Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.34 |
| ▸ | APP | P05067 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.31 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6917419 | 0.76 | STS (0.49) | STSALDH1A1HSD17B10CYP2B6CYP1A2 | |
| SCHEMBL276961 | 0.72 | STS (0.53) | STSCYP2B6CYP1A2CYP1B1 | |
| SCHEMBL29274342 | 0.72 | STS (0.49) | STSTSHRCYP2B6CYP1A2CYP1B1 | |
| SCHEMBL30065900 | 0.72 | STS (0.53) | STSALDH1A1CYP2B6CYP1A2CYP1B1 | |
| SCHEMBL2011444 | 0.72 | STS (0.49) | STSCYP2B6CYP1A2CYP1B1 | |
| SCHEMBL5537604 | 0.72 | STS (0.49) | STSCYP2B6CYP1A2CYP1B1 | |
| SCHEMBL547263 | 0.72 | STS (0.49) | STSAPPCYP2B6 | |
| SCHEMBL4150416 | 0.72 | STS (0.49) | STSCYP2B6CYP1A2CYP1B1 | |
| SCHEMBL10426769 | 0.72 | STS (0.53) | STSALDH1A1CYP2B6CYP1A2CYP1B1 | |
| SCHEMBL29771885 | 0.72 | STS (0.49) | STSAPPCYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225487-B2 | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20210061812-A1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC. | 2021-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225487-B2 | 7-membered aza-heterocyclic containing δ-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | STS 4630/4885ALDH1A1 854/4885TSHR 495/4885 |
| US-20210061812-A1 | 7-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | STS 4640/4885ALDH1A1 894/4885TSHR 498/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.